# Borderline resectable pancreatic ductal adenocarcinoma

Source: https://onco.cc/cancers/borderline-resectable-pdac/  
OnCo record `borderline-resectable-pdac` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal.

## Summary

Borderline resectable disease is defined anatomically: tumour contact with the superior mesenteric or portal vein that is reconstructable, abutment of the superior mesenteric artery of 180 degrees or less, or limited contact with the hepatic artery. The MD Anderson, NCCN and international consensus definitions differ in detail and some add biological criteria, such as a very high CA 19-9 or suspicious regional nodes, and conditional criteria such as poor performance status. The point of the category is that upfront surgery leaves a positive margin in a large share of patients and that neoadjuvant treatment selects those who will benefit from a difficult operation.

Neoadjuvant therapy is standard. PREOPANC-1 (2020, long-term follow-up 2022) randomised resectable and borderline patients to gemcitabine-based chemoradiation before surgery or upfront surgery and found more clear-margin resections and better long-term survival, with the benefit concentrated in the borderline group. PREOPANC-2 then compared neoadjuvant FOLFIRINOX with gemcitabine chemoradiation and found no difference, and ESPAC-5 found that neoadjuvant chemotherapy beat immediate surgery for borderline disease. Modified FOLFIRINOX for two to four months is the usual regimen, with gemcitabine plus nab-paclitaxel for less fit patients. The role of radiotherapy after chemotherapy is disputed: ALLIANCE A021501 (2022) stopped its stereotactic radiotherapy arm early because outcomes were worse than with chemotherapy alone, while other groups use conventional or ablative chemoradiation to secure the arterial margin.

After neoadjuvant treatment patients are restaged with CT and CA 19-9; radiological shrinkage is often modest even when the tumour has responded, so surgeons operate on patients with stable disease, falling CA 19-9 and good fitness. Resection with venous reconstruction is routine in specialist centres and arterial resection is done selectively. Pathological response predicts survival, and patients complete a total of six months of chemotherapy after surgery where possible. Germline testing is offered to all, and a BRCA or PALB2 variant argues for a platinum-containing regimen. Trials are adding RAS inhibitors and vaccines to neoadjuvant chemotherapy and testing circulating tumour DNA to decide who should proceed to surgery.

## Fields

- Kind: Cancer
- Last checked: 2026-09-18
- Also known as: Borderline resectable pancreatic cancer; BRPC; Marginally resectable pancreatic cancer
- Tags: subtype-page; gastrointestinal
- Group: gastrointestinal
- Burden: A fifth or so of newly diagnosed pancreatic cancers touch a major vein or artery enough to make a clear-margin operation uncertain; how many are called borderline depends on the surgeon and the definition used.
- Subtypes: Borderline resectable PDAC with venous involvement only (reconstructable portal or superior mesenteric vein); Borderline resectable PDAC with limited arterial abutment (superior mesenteric or hepatic artery); Biologically borderline PDAC (very high CA 19-9 or suspicious nodes with resectable anatomy); Borderline resectable PDAC converted to resection after FOLFIRINOX; Borderline resectable PDAC that progresses during neoadjuvant therapy (treated as advanced disease)
- Biomarkers: Pancreas-protocol CT with degrees of vessel contact (defines the category); CA 19-9 trend during neoadjuvant chemotherapy (falling levels predict a useful operation); Restaging CT after chemotherapy (stable disease is acceptable; shrinkage is often modest); Germline BRCA1, BRCA2, PALB2 and ATM status (platinum choice); Pathological response grade and margin status after resection; Circulating tumour DNA before surgery (investigational selection marker)

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/borderline-resectable-pdac/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/borderline-resectable-pdac/#overview [4 state-of-the-art points]
- Types and stages (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/borderline-resectable-pdac/#what-it-is [5 subtypes]
- Symptoms and diagnosis (on the hub): How this cancer shows itself, how the diagnosis is confirmed, and the biomarkers clinicians test for. https://onco.cc/cancers/borderline-resectable-pdac/#finding-it [6 biomarkers]
- Treatment (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/borderline-resectable-pdac/#treating-it [5 settings, 4 decisions with options]
- Trials and papers (own page): Trials recruiting now, the landmark trials, the trials held by this cancer's subtypes, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/borderline-resectable-pdac/evidence/ [40 trials, 7 key papers, 6 milestones]
- Biology and targets (on the hub): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/borderline-resectable-pdac/#science [2 targets, 2 pathways]
- Countries and centres (own page): Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes. https://onco.cc/cancers/borderline-resectable-pdac/where-you-are/ [32 UK centres]
- Decisions and support (on the hub): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/borderline-resectable-pdac/#living-with-it [19 questions, 4 red cards, 1 decision aid]
- Pipeline and open problems (own page): Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/borderline-resectable-pdac/coming/ [7 medicines, 38 trials, 3 ideas, 4 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/borderline-resectable-pdac/data/ [103 connected records]

## Standard of care

- Neoadjuvant chemotherapy: Modified FOLFIRINOX for two to four months in fit patients, gemcitabine plus nab-paclitaxel otherwise; restage with CT and CA 19-9 before deciding on surgery (PREOPANC, ESPAC-5). ([FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/), [PREOPANC-1](https://onco.cc/trials/preopanc/), [CA 19-9](https://onco.cc/terms/ca19-9/), [Neoadjuvant / adjuvant / perioperative](https://onco.cc/terms/neoadjuvant-adjuvant/), [ESPAC-5](https://onco.cc/trials/espac-5/))
- Radiotherapy after chemotherapy: Optional; conventional chemoradiation or stereotactic radiotherapy to secure an arterial margin in selected patients, with ALLIANCE A021501 as the caution against routine use. ([Chemoradiation (chemoradiotherapy, CRT)](https://onco.cc/terms/chemoradiation/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [MR-guided adaptive radiotherapy](https://onco.cc/technologies/mr-linac/), [Capecitabine](https://onco.cc/drugs/capecitabine/))
- Surgery: Pancreatoduodenectomy or distal pancreatectomy with venous resection and reconstruction where needed, arterial resection only in specialist centres; proceed on stable or improved disease with falling CA 19-9. ([Whipple procedure (pancreaticoduodenectomy)](https://onco.cc/terms/whipple/), [Resection margins (R0 / R1 / R2)](https://onco.cc/terms/resection-margins/), [Resectable, borderline resectable and unresectable](https://onco.cc/terms/resectability/), [Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/))
- After surgery: Complete six months of chemotherapy in total, usually with the regimen the tumour responded to. ([FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Capecitabine](https://onco.cc/drugs/capecitabine/))
- Progression during neoadjuvant therapy: Manage as locally advanced or metastatic disease; switch chemotherapy backbone, RAS inhibitor trials, biliary stenting for jaundice. ([NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)](https://onco.cc/drugs/nalirifox/), [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Biliary stenting and drainage](https://onco.cc/technologies/biliary-stenting-drainage/))

## State of the art

- Neoadjuvant chemotherapy is the standard for borderline disease, with modified FOLFIRINOX the usual regimen (PREOPANC, ESPAC-5).
- Venous resection and reconstruction is routine in high-volume centres and no longer a reason to call a tumour unresectable.
- The role of radiotherapy is being redefined after ALLIANCE A021501, with ablative and MR-guided techniques in trials.
- RAS inhibitors and vaccines are entering neoadjuvant trials for the first time.

## Open problems

- Definitions of borderline disease differ between centres, so trial populations are not comparable.
- CT underestimates response after chemotherapy, and there is no validated marker to tell fibrosis from viable tumour before surgery.
- Whether radiotherapy adds anything after modern chemotherapy is unresolved.
- Arterial resection carries high morbidity and its benefit is unproven outside expert centres.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Pancreatic_cancer
- Wikipedia: https://en.wikipedia.org/wiki/Pancreatic_cancer
- NCCN Guidelines: Pancreatic Adenocarcinoma: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455

## Connected records

- cancers: [BRCA or PALB2-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/brca-palb2-pdac/), [KRAS G12C-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-g12c-pdac/), [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Biliary stenting and drainage](https://onco.cc/technologies/biliary-stenting-drainage/), [CT (computed tomography)](https://onco.cc/technologies/ct/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MR-guided adaptive radiotherapy](https://onco.cc/technologies/mr-linac/), [PDAC organoid pharmacotyping](https://onco.cc/technologies/pdac-organoid-pharmacotyping/), [Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [KRAS](https://onco.cc/targets/kras/)
- drugs: [Autogene cevumeran](https://onco.cc/drugs/autogene-cevumeran/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/), [NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)](https://onco.cc/drugs/nalirifox/)
- companies: [BioNTech](https://onco.cc/companies/biontech/), [Dutch Pancreatic Cancer Group](https://onco.cc/companies/dpcg/), [Revolution Medicines](https://onco.cc/companies/revolution-medicines/)
- pathways: [Fibroblast activation, desmoplasia & matrix stiffness](https://onco.cc/pathways/caf-activation-desmoplasia/), [Pancreatic cancer (KEGG map)](https://onco.cc/pathways/pancreatic-cancer-signalling/)
- terms: [CA 19-9](https://onco.cc/terms/ca19-9/), [Chemoradiation (chemoradiotherapy, CRT)](https://onco.cc/terms/chemoradiation/), [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Locally advanced and locoregional disease](https://onco.cc/terms/locally-advanced/), [Neoadjuvant / adjuvant / perioperative](https://onco.cc/terms/neoadjuvant-adjuvant/), [Neoadjuvant therapy versus surgery first for resectable and borderline resectable pancreatic cancer](https://onco.cc/terms/neoadjuvant-versus-upfront-surgery-pancreatic/), [Pancreas protocol CT (pancreatic protocol CT, dual-phase thin-slice CT with structured reporting)](https://onco.cc/terms/pancreas-protocol-ct/), [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/), [R0 and R1 margins in pancreatic cancer: the 1 mm rule and standardised specimen reporting](https://onco.cc/terms/r0-r1-margin-pancreatic/), [Resectability classes for pancreatic cancer (NCCN anatomical criteria and the 2017 international consensus)](https://onco.cc/terms/nccn-resectability-criteria-pancreatic/), [Resectable, borderline resectable and unresectable](https://onco.cc/terms/resectability/), [Resection margins (R0 / R1 / R2)](https://onco.cc/terms/resection-margins/), [Stereotactic body radiotherapy (SBRT / SABR)](https://onco.cc/terms/sbrt-term/), [Vascular resection in pancreatic cancer surgery (portal and superior mesenteric vein resection; arterial resection)](https://onco.cc/terms/vascular-resection-pancreatic/), [Whipple procedure (pancreaticoduodenectomy)](https://onco.cc/terms/whipple/)
- trials: [24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC](https://onco.cc/trials/nct07043270/), [A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer](https://onco.cc/trials/nct06944106/), [AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.](https://onco.cc/trials/nct07208539/), [Alliance A021501](https://onco.cc/trials/alliance-a021501/), [Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel](https://onco.cc/trials/nct06483555/), [Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver](https://onco.cc/trials/nct06690528/), [DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer](https://onco.cc/trials/nct07705919/), [EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer](https://onco.cc/trials/nct07698613/), [ESPAC-5](https://onco.cc/trials/espac-5/), [Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer](https://onco.cc/trials/nct06423326/), [HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation](https://onco.cc/trials/nct07240766/), [Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer](https://onco.cc/trials/nct06435260/), [IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer](https://onco.cc/trials/nct07415525/), [Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source](https://onco.cc/trials/nct02843945/), [Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer](https://onco.cc/trials/nct07539155/), [Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pan](https://onco.cc/trials/nct07542002/), [Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)](https://onco.cc/trials/nct06384560/), [Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer](https://onco.cc/trials/nct05562297/), [Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer](https://onco.cc/trials/nct07277452/), [NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101](https://onco.cc/trials/nct05984810/), [Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial](https://onco.cc/trials/nct03322995/), [PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)](https://onco.cc/trials/nct07477418/), [PREOPANC-1](https://onco.cc/trials/preopanc/), [PREOPANC-2](https://onco.cc/trials/preopanc-2/), [Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma](https://onco.cc/trials/nct05083247/), [PRODIGE 24 / CCTG PA6](https://onco.cc/trials/prodige-24/), [Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas](https://onco.cc/trials/nct02598349/), [PULSAR in Systemic Therapy for Pancreatic Cancer](https://onco.cc/trials/nct07269626/), [Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC](https://onco.cc/trials/nct06573398/), [Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX](https://onco.cc/trials/nct07044453/), [SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial](https://onco.cc/trials/nct07748611/), [Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC](https://onco.cc/trials/nct06714604/), [Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer](https://onco.cc/trials/nct06259058/), [Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma](https://onco.cc/trials/nct07126158/), [Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma](https://onco.cc/trials/nct05241249/), [Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)](https://onco.cc/trials/nct07252232/), [Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC](https://onco.cc/trials/nct07833241/), [Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable P](https://onco.cc/trials/nct07436741/), [Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer](https://onco.cc/trials/nct07469956/), [Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer](https://onco.cc/trials/nct05836870/)
- people: [Albert C. Koong](https://onco.cc/people/albert-koong/), [Eileen M. O'Reilly](https://onco.cc/people/eileen-oreilly/), [Jürgen Weitz](https://onco.cc/people/jurgen-weitz/), [Marc G. Besselink](https://onco.cc/people/marc-besselink/), [Paula Ghaneh](https://onco.cc/people/paula-ghaneh/), [Richard Schulick](https://onco.cc/people/richard-schulick/), [Theodore S. Hong](https://onco.cc/people/theodore-hong/)
- key papers: [Alliance A021501: preoperative modified FOLFIRINOX with or without hypofractionated radiotherapy for borderline resectable pancreatic cancer](https://onco.cc/key-papers/paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022/), [Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer](https://onco.cc/key-papers/paper-bernard-ctdna-exodna-pancreatic-gastroenterology-2019/), [Conroy 2011: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11)](https://onco.cc/key-papers/paper-conroy-folfirinox-pancreatic-nejm-2011/), [ESPAC5: immediate surgery versus short-course neoadjuvant chemotherapy or chemoradiotherapy for borderline resectable pancreatic cancer](https://onco.cc/key-papers/paper-espac-5-neoadjuvant-borderline-resectable-pancreatic-lancet-gastro-hep-2023/), [Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial](https://onco.cc/key-papers/paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025/), [PREOPANC long-term results: neoadjuvant gemcitabine-based chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer](https://onco.cc/key-papers/paper-preopanc-neoadjuvant-chemoradiotherapy-long-term-jco-2022/), [Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial](https://onco.cc/key-papers/paper-preopanc-preoperative-chemoradiotherapy-jco-2020/)
- ideas: [Chemotherapy before surgery for every resectable pancreatic cancer, settled by the two perioperative trials rather than assumed](https://onco.cc/ideas/idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease/), [Grow each trial patient's tumour as organoids to decide which platform arm opens next](https://onco.cc/ideas/idea-tr2-organoid-coclinical-arms/), [RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable](https://onco.cc/ideas/idea-ras-inhibitor-neoadjuvant-pdac/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/borderline-resectable-pdac.json